Latest Breaking News On - Armand rigaudy - Page 2 : vimarsana.com

SpikImm, a Biotechnology Company Founded by Truffle Capital Under License from the Institut Pasteur, Announces that the Clinical Trials for SPK001, its Monoclonal Antibody Against SARS-COV-2, Have Begun

This Clinical Trial Has Been Awarded National Priority Research Status by the French Government SPK001, the first anti-SARS Cov2 monoclonal antibody candidate of SpikImm, a French biotechnology company

Kaufman & Broad SA: RESULTS OF THE FIRST NINE -3-

DJ Kaufman & Broad SA: RESULTS OF THE FIRST NINE MONTHS OF THE 2022 BUSINESS YEAR Kaufman & Broad SA Kaufman & Broad SA: RESULTS OF THE FIRST NINE MONTHS OF THE 2022 BUSINESS YEAR 03-Oct-2022 / 18:58

Kaufman & Broad SA: RESULTS OF THE FIRST NINE -4-

DJ Kaufman & Broad SA: RESULTS OF THE FIRST NINE MONTHS OF THE 2022 BUSINESS YEAR Kaufman & Broad SA Kaufman & Broad SA: RESULTS OF THE FIRST NINE MONTHS OF THE 2022 BUSINESS YEAR 03-Oct-2022 / 18:58

Kaufman & Broad SA: RESULTS OF THE FIRST NINE -2-

FITCH ASSIGNS AN INVESTMENT GRADE BBB- RATING TO KAUFMAN & BROAD

DJ FITCH ASSIGNS AN INVESTMENT GRADE BBB- RATING TO KAUFMAN & BROAD Kaufman & Broad SA FITCH ASSIGNS AN INVESTMENT GRADE BBB- RATING TO KAUFMAN & BROAD 29-Sep-2022 / 22:30 CET/CEST Dissemination of